Login or Register to unlock everything MedSchool has to offer!

Monoclonal Antibodies

 
 
 
Immunotherapy
Haematologic Malignancies
Solid Organ Malignancies
Other
 
 

Anti-EGFR (HER1) Antibodies

 
 
  •  
    IV
    Cetuximab
    Erbitux 
  •  
    IV
    Panitumumab
    Vectibix 
    • Mechanism of Action
    • Monoclonal antibodies directed against epidermal growth factor receptor (EGFR / HER1), which is involved in cell signalling and is overexpressed in certain cancers. Inhibition of EGFR signalling pathways results in cell cycle arrest.

Clinical Use

    • Indications
    • Metastatic colorectal cancer that is EGFR positive, RAS wild type
    • Locally advanced / metastatic squamous cell cancer of the head & neck (cetuximab)
    • Contraindications
    • May not be used in the presence of RAS or BRAF mutations (must be wild type).
    • Adverse Effects
    • Acneiform rash
    • Nausea / vomiting / diarrhoea / constipation
    • Abdominal pain
    • Headache
    • Fatigue
    • Anorexia
    • Hypomagnesaemia
    • Elevated LFTs
    • Anaemia
 
----------------------------------------------------------------------------------------------------------------------------------------------------------------------------
 
Read More...
Feedback